Worth reading
72In focus
Scored from 4 of 6 sectionsDirection
Deterioration
Direction inferred from the company’s description.Scale
-560320
千円（連結営業損失）Wording
Conditional
How definitive the wording is.Results for this period
Third quarter2023年7月1日〜2024年3月31日ConsolidatedJapanese GAAPNet Sales3,841,269¥ thousandYear on year -41.7%
Operating profit-560,320¥ thousand
Ordinary income-529,187¥ thousand
Net income attributable to owners of the parent-574,532¥ thousand
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
Financial position at period-end
Total assets6,977,552¥ thousand
of which net assets 6,337,023 ¥ thousand
The shaded area represents net assets as a proportion of total assets. It is calculated from the two amounts reported by the company.
Segment revenueBiological Assessment Systems ¥192,314 thousand (YoY -52.5%), Healthcare Support ¥490,249 thousand (YoY +5.8%), Cosmetics ¥982,014 thousand (YoY -71.2%), Health Supplements ¥1,933,466 thousand (YoY +0.5%), Functional Materials Development ¥242,024 thousand (YoY -36.3%)
Segment profitBiological Assessment Systems ¥-51,150 thousand, Healthcare Support ¥77,640 thousand, Cosmetics ¥-177,462 thousand, Health Supplements ¥-183,959 thousand, Functional Materials Development ¥-686 thousand
Outlook and shareholder returns
Revision to Earnings ForecastNo change
Factors Behind Changes in Business Performance
生体評価システムは評価試験・医薬臨床研究支援の売上減少、化粧品は中国市場での日本製品の不買運動激化と現地メーカー台頭による競争激化、健康補助食品は原材料価格・広告料の高騰、機能性素材開発は原材販売数量の伸び悩みが主な要因。
Disclosure regarding the going concern assumption
No applicable matters.
Impairment lossNo applicable matters.
Breakdown of extraordinary income (loss)Extraordinary income Not disclosed / Extraordinary loss Loss on sale of fixed assets ¥134 thousand
Orders received and order backlogBusiness Evaluation Testing Business / Orders received ¥280 million / Order backlog ¥230 million, Business 医薬臨床研究支援事業 / Orders received ¥55 million / Order backlog ¥41 million, Business Healthcare support business / Orders received ¥490 million / Order backlog No
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2023年7月1日〜2024年3月31日 |
| Net Sales | ¥3,841,269 thousand (YoY -41.7%) |
| Operating profit | ¥-560,320 thousand |
| Ordinary income | ¥-529,187 thousand |
| Profit attributable to owners of the parent | ¥-574,532 thousand |
| Total assets | ¥6,977,552 thousand |
| Net assets | ¥6,337,023 thousand |
| Revision to Earnings Forecast | No change |
| Segment revenue | Biological Assessment Systems ¥192,314 thousand (YoY -52.5%), Healthcare Support ¥490,249 thousand (YoY +5.8%), Cosmetics ¥982,014 thousand (YoY -71.2%), Health Supplements ¥1,933,466 thousand (YoY +0.5%), Functional Materials Development ¥242,024 thousand (YoY -36.3%) |
| Segment profit | Biological Assessment Systems ¥-51,150 thousand, Healthcare Support ¥77,640 thousand, Cosmetics ¥-177,462 thousand, Health Supplements ¥-183,959 thousand, Functional Materials Development ¥-686 thousand |
| Orders received and order backlog | Business Evaluation Testing Business / Orders received ¥280 million / Order backlog ¥230 million, Business 医薬臨床研究支援事業 / Orders received ¥55 million / Order backlog ¥41 million, Business Healthcare support business / Orders received ¥490 million / Order backlog No |
| Impairment loss | No applicable matters. |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Loss on sale of fixed assets ¥134 thousand |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Factors Behind Changes in Business Performance | 生体評価システムは評価試験・医薬臨床研究支援の売上減少、化粧品は中国市場での日本製品の不買運動激化と現地メーカー台頭による競争激化、健康補助食品は原材料価格・広告料の高騰、機能性素材開発は原材販売数量の伸び悩みが主な要因。 |
Items this document does not state (20)
Net income per shareOperating MarginEquity ratioCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodFull-year earnings forecastAnnual Dividend ForecastPayout ratioShareholder Return PolicyRegional salesDepreciation and amortizationChange in accounting policyChanges in the scope of consolidationMaterial subsequent eventsAvailability of Supplementary Financial Results MaterialsAvailability of Financial Results BriefingIssued Shares at Period-EndTreasury Shares at Period-End
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.化粧品事業では、中国市場向け商品が日本製品の不買運動の激化や現地メーカーとの競争激化の影響を受けて減収となった。健康補助食品事業では原材料価格や広告料の高騰、生体評価システム事業では評価試験・医薬臨床研究支援の売上減少が業績に影響した。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.